New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
09:26 EDTCTICCell Therapeutics price target raised to $7 from $6 at Roth Capital
Roth Capital increased its price target on Cell Therapeutics as the firm thinks the company's AK2/FLT3 inhibitor, Pacritinib, is evolving quite favorably. The firm believes that two of the company's other drugs, ixuvri and tosedostat, have positive potential. Roth reiterates a Buy rating on the stock.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 17, 2015
12:38 EDTCTICCTI BioPharma management to meet with Piper Jaffray
Subscribe for More Information
March 16, 2015
09:15 EDTCTICCTI BioPharma shares should be bought on weakness, says Roth Capital
Subscribe for More Information
05:27 EDTCTICCTI BioPharma announces publication of Phase 2 pacritinib study results
Subscribe for More Information
March 13, 2015
10:09 EDTCTICHigh option volume stocks
High option volume stocks: ULTA HOG CTIC CTL LOCO IMPV BMRN IMOS ATHX GALE
09:25 EDTCTICOn The Fly: Pre-market Movers
UP AFTER EARNINGS: FXCM (FXCM), up 15.8%... El Pollo LoCo (LOCO), up 9.9%... Ulta Salon (ULTA), up 7.1%... Hibbett Sports (HIBB), up 5.1%... Ann Inc (ANN), up 5.5%... Spectrum Pharmaceuticals (SPPI), up 2.9%. ALSO HIGHER: Herbalife (HLF), up 5.1% following a Wall Street Journal report that federal prosecutors are investigating potential stock manipulation... Mobileye (MBLY), up 4.7% after being upgraded at Goldman... NXP Semiconductors (NXPI), up 1.7% after being initiated with a Strong Buy at Needham. DOWN AFTER EARNINGS: Aeropostale (ARO), down 13.2%... CTI BioPharma (CTIC), down 7.7%... Civeo (CVEO), down 3.4%. ALSO LOWER: Galena Biopharma (GALE), down 10.4% after announcing public offering of common stock and warrants... Whiting Petroleum (WLL), down 7.6% following a report from Reuters that explains that the company looks to sell certain assets instead of the whole company... Continental Building (CBPX), down 7.5% after 5M share Spot Secondary priced at $19.70.
March 12, 2015
19:25 EDTCTICOn The Fly: After Hours Movers
Subscribe for More Information
16:07 EDTCTICCTI BioPharma sees 2015 revenue $50M-$55M, consensus $50.2M
Sees 2015 operating loss $75M-$85M.
16:06 EDTCTICCTI BioPharma reports Q4 EPS (27c), consensus (18c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use